Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 62 articles:
HTML format
Text format



Single Articles


    April 2019
  1. NARDI V
    Case 35-2018: A Woman with Back Pain and a Remote History of Breast Cancer. Reply.
    N Engl J Med. 2019;380.
    PubMed     Text format    


  2. FOULKES WD, Witkowski L
    Case 35-2018: A Woman with Back Pain and a Remote History of Breast Cancer.
    N Engl J Med. 2019;380.
    PubMed     Text format    


    March 2019
  3. MEHTA RS, Barlow WE, Albain KS, Vandenberg TA, et al
    Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
    N Engl J Med. 2019;380:1226-1234.
    PubMed     Text format     Abstract available


  4. SCHMID P, Chui SY, Emens LA
    Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Reply.
    N Engl J Med. 2019;380:987-988.
    PubMed     Text format    


  5. ALTUNDAG K
    Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2019;380:986-987.
    PubMed     Text format    


  6. O'SULLIVAN H, Collins D, O'Reilly S
    Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2019;380:986.
    PubMed     Text format    


  7. AKTAS BY, Taban H, Aksoy S
    Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2019;380:985-986.
    PubMed     Text format    


    February 2019
  8. MCCAW ZR, Vassy JL, Wei LJ
    Palbociclib and Fulvestrant in Breast Cancer.
    N Engl J Med. 2019;380:796.
    PubMed     Text format    


  9. TURNER NC, Huang X, Cristofanilli M
    Palbociclib and Fulvestrant in Breast Cancer. Reply.
    N Engl J Med. 2019;380:797.
    PubMed     Text format    


  10. NAIK RD, Batra A, Gupta VG
    Palbociclib and Fulvestrant in Breast Cancer.
    N Engl J Med. 2019;380:796.
    PubMed     Text format    


  11. BARDIA A, Mayer IA, Vahdat LT, Tolaney SM, et al
    Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
    N Engl J Med. 2019;380:741-751.
    PubMed     Text format     Abstract available


  12. PROWELL TM, Beaver JA, Pazdur R
    Residual Disease after Neoadjuvant Therapy - Developing Drugs for High-Risk Early Breast Cancer.
    N Engl J Med. 2019;380:612-615.
    PubMed     Text format    


  13. HAYES DF
    Further Progress for Patients with Breast Cancer.
    N Engl J Med. 2019;380:676-677.
    PubMed     Text format    



  14. Lymphedema after Breast Cancer Treatment.
    N Engl J Med. 2019;380:694.
    PubMed     Text format    


  15. JINDEEL A
    Lymphedema after Breast Cancer Treatment.
    N Engl J Med. 2019;380:694.
    PubMed     Text format    


    January 2019
  16. DEFILIPPIS EM, Nohria A, Burstein HJ, Doyle LA, et al
    A Breath-Taking Diagnosis.
    N Engl J Med. 2019;380:81-87.
    PubMed     Text format    


    December 2018

  17. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
    N Engl J Med. 2018;379:2582.
    PubMed     Text format    


  18. VON MINCKWITZ G, Huang CS, Mano MS, Loibl S, et al
    Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
    N Engl J Med. 2018 Dec 5. doi: 10.1056/NEJMoa1814017.
    PubMed     Text format     Abstract available


    November 2018
  19. ROCKSON SG
    Lymphedema after Breast Cancer Treatment.
    N Engl J Med. 2018;379:1937-1944.
    PubMed     Text format    


  20. BARDIA A, Hovnanian MD, Brachtel EF, Nardi V, et al
    Case 35-2018: A 68-Year-Old Woman with Back Pain and a Remote History of Breast Cancer.
    N Engl J Med. 2018;379:1946-1953.
    PubMed     Text format    


    October 2018
  21. CHLEBOWSKI RT, Pan K
    Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    N Engl J Med. 2018;379:1684.
    PubMed     Text format    


  22. PATEL A, Gupta VG
    Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    N Engl J Med. 2018;379:1683-4.
    PubMed     Text format    


  23. LOVE RR
    Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    N Engl J Med. 2018;379:1683.
    PubMed     Text format    


  24. NEWMAN LA
    Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer.
    N Engl J Med. 2018;379:1681-2.
    PubMed     Text format    


  25. MCCAW ZR, Wei LJ, Kim DH
    Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer.
    N Engl J Med. 2018;379:1681.
    PubMed     Text format    


  26. CHENG Y, Wu Y, Wu L
    Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer.
    N Engl J Med. 2018;379:1680-1.
    PubMed     Text format    



  27. Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    N Engl J Med. 2018;379:1683-1685.
    PubMed     Text format    



  28. Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer.
    N Engl J Med. 2018;379:1680-1682.
    PubMed     Text format    


  29. SCHMID P, Adams S, Rugo HS, Schneeweiss A, et al
    Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2018 Oct 20. doi: 10.1056/NEJMoa1809615.
    PubMed     Text format     Abstract available


  30. TURNER NC, Slamon DJ, Ro J, Bondarenko I, et al
    Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
    N Engl J Med. 2018 Oct 20. doi: 10.1056/NEJMoa1810527.
    PubMed     Text format     Abstract available



  31. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations; Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
    N Engl J Med. 2018;379:1585.
    PubMed     Text format    



  32. Breast Cancer in Men.
    N Engl J Med. 2018;379:1385-1386.
    PubMed     Text format    


  33. KANAKIS GA, Jorgensen N, Goulis DG
    Breast Cancer in Men.
    N Engl J Med. 2018;379:1385.
    PubMed     Text format    


    August 2018
  34. LITTON JK, Rugo HS, Ettl J, Hurvitz SA, et al
    Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
    N Engl J Med. 2018 Aug 15. doi: 10.1056/NEJMoa1802905.
    PubMed     Text format     Abstract available


    July 2018
  35. STEARNS V
    TAILORing Adjuvant Systemic Therapy for Breast Cancer.
    N Engl J Med. 2018;379:191-192.
    PubMed     Text format    


    June 2018
  36. GIORDANO SH
    Breast Cancer in Men.
    N Engl J Med. 2018;378:2311-2320.
    PubMed     Text format    


  37. MULASI I
    The Scarlet Virus.
    N Engl J Med. 2018;378:2157-2159.
    PubMed     Text format    


  38. FRANCIS PA, Pagani O, Fleming GF, Walley BA, et al
    Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    N Engl J Med. 2018 Jun 4. doi: 10.1056/NEJMoa1803164.
    PubMed     Text format     Abstract available


  39. LIPPMAN ME
    Endocrine Adjuvant Therapy for Localized Breast Cancer.
    N Engl J Med. 2018 Jun 4. doi: 10.1056/NEJMe1806130.
    PubMed     Text format    


  40. SPARANO JA, Gray RJ, Makower DF, Pritchard KI, et al
    Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
    N Engl J Med. 2018 Jun 3. doi: 10.1056/NEJMoa1804710.
    PubMed     Text format     Abstract available


    May 2018
  41. ELMORE SNC
    p53 and Me.
    N Engl J Med. 2018;378:1962-1963.
    PubMed     Text format    


    March 2018
  42. NACHTIGALL L, Naftolin F, Keefe DL
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1265.
    PubMed     Text format    


  43. CRAMER DW, Braaten K
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1264-8.
    PubMed     Text format    


  44. ROBERTS K, Merkatz RB, Vieira CS
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1264.
    PubMed     Text format    


  45. WOOD S
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1264.
    PubMed     Text format    


  46. SCHWARZ EB, Foster DG, Grossman D
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1263-4.
    PubMed     Text format    



  47. Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1263-1266.
    PubMed     Text format    



  48. Breast-Cancer Recurrence after Stopping Endocrine Therapy.
    N Engl J Med. 2018;378:870-871.
    PubMed     Text format    


  49. ANDERSON GM
    Breast-Cancer Recurrence after Stopping Endocrine Therapy.
    N Engl J Med. 2018;378:870.
    PubMed     Text format    


    January 2018
  50. VAN DEN HEUVELEIBRINK MM, van der Kooi ALF, Wallace WHB
    Fertility Preservation in Women.
    N Engl J Med. 2018;378:399-400.
    PubMed     Text format    


  51. DONNEZ J, Dolmans MM
    Fertility Preservation in Women.
    N Engl J Med. 2018;378:400-401.
    PubMed     Text format    


    December 2017
  52. TURNER NC
    Signatures of DNA-Repair Deficiencies in Breast Cancer.
    N Engl J Med. 2017;377:2490-2492.
    PubMed     Text format    


  53. MORCH LS, Skovlund CW, Hannaford PC, Iversen L, et al
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2017;377:2228-2239.
    PubMed     Text format     Abstract available


  54. DEMICHELE A, Yee D, Esserman L
    Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer.
    N Engl J Med. 2017;377:2287-2289.
    PubMed     Text format    


  55. HUNTER DJ
    Oral Contraceptives and the Small Increased Risk of Breast Cancer.
    N Engl J Med. 2017;377:2276-2277.
    PubMed     Text format    


    November 2017
  56. PAN H, Gray R, Braybrooke J, Davies C, et al
    20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
    N Engl J Med. 2017;377:1836-1846.
    PubMed     Text format     Abstract available


  57. NAROD S, Booth CM, Foulkes WD
    Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.
    N Engl J Med. 2017;377:1792.
    PubMed     Text format    


  58. OIDE T, Mitsuishi T
    Pigmented Macule - A Skin Manifestation of Invasive Breast Cancer.
    N Engl J Med. 2017;377:1777.
    PubMed     Text format    



  59. Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.
    N Engl J Med. 2017;377:1792-3.
    PubMed     Text format    


  60. GREENE AK, Voss SD, Maclellan RA
    Liposuction for Swelling in Patients with Lymphedema.
    N Engl J Med. 2017;377:1788-1789.
    PubMed     Text format    


    October 2017
  61. LEMERY S, Keegan P, Pazdur R
    First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.
    N Engl J Med. 2017;377:1409-1412.
    PubMed     Text format    


    September 2017
  62. RAMASWAMI R, Morrow M, Jagsi R
    Contralateral Prophylactic Mastectomy.
    N Engl J Med. 2017;377:1288-1291.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: